| Summary: | Background:
Metastasis-Associated in Colon Cancer 1(<i>MACC1</i>) is a validated biomarker for metastasis and is linked to survival. Although extensive experimental evidence indicates an association between <i>MACC1</i> and diverse cancers, no pan-cancer analyses have yet been performed for this marker, and the role of <i>MACC1</i> in immunology remains unknown.
Material and Methods:
In our study, we performed the analysis of <i>MACC1</i> expression and its influence on prognosis using multiple databases, including TIMER2, GEPIA2, Kaplan-Meier plotter. <i>MACC1</i> promoter methylation levels were evaluated using the UALCAN database. Based on the TCGA database, we explored the relationship between <i>MACC1</i> and tumor mutational burden (TMB), microsatellite instability (MSI), immune checkpoints using the R programming language. We evaluated the association between <i>MACC1</i> and immune infiltration via TIMER and UALCAN.
Results:
Our results revealed that abnormal DNA methylation may be an important cause for the different expression of <i>MACC1</i> across cancer types. Meanwhile, we explored the potential oncogenic roles of <i>MACC1</i> and found significant prognostic value. <i>MACC1</i> may be related to T-cell function and the polarization of tumor-associated macrophages, especially in STAD and LGG. Its expression was associated with immune infiltration and was found to be closely related to immune checkpoint-associated genes, especially CD274 and SIGLEC15, indicating that <i>MACC1</i> may be a potential immune therapeutic target for several malignancies. Our paper reveals for the first time the relationship between <i>MACC1</i> and cancer immunology.
Conclusions:
<i>MACC1</i> might act as a predictor for the immune response in cancer patients, and could also represent a new potential immunotherapeutic target.
|
|---|